Stockreport

Natera to work with Exelixis on latter's zanzalintinib phase 3 trial [Seeking Alpha]

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF for enrollment in a phase 3 trial of Exelixis' ( EXEL ) zanzalintinib for resected stage II/III colorectal cancer. The primary endpoint of the STELLAR-316 study, which [Read more]